What it does
CJC-1295 / Ipamorelin pairs two complementary GH secretagogues in a fixed-ratio vial. CJC-1295 (no-DAC, i.e. Modified GRF 1-29) binds the GHRH receptor on the anterior pituitary and amplifies the natural GH pulse; Ipamorelin selectively activates the ghrelin/GHSR-1a receptor to trigger GH release without raising cortisol, prolactin, or aldosterone. Together they produce a synergistic GH pulse that resembles natural physiology more closely than either peptide alone or exogenous hGH.
Used for
Dose
- Dose
- 250 mcg · 5 days/week (10 units of a 5/5 mg vial = 250 mcg of each)
- When
- Bedtime30–60 minutes before bed, fasted 2+ hours, pairs the injected pulse with the natural overnight GH window in slow-wave sleep; recent insulin blunts the ghrelin pathway.
- How long
- 6 months on / 2 months off
- Site
- subcutaneous, before bed, fasted 2+ h
- Food
- fasted
Need exact volumes? Open the peptide calculator →
⚠ Caution
- Active malignancy (theoretical concern via IGF-1; relative)
- Uncontrolled diabetes or severe insulin resistance (GH is counter-regulatory to insulin; transient increases in insulin resistance)
- Severe heart failure
- Pituitary or hypothalamic disease — confirm with provider before use
- Pregnancy and breastfeeding
- Competitive athletes — GH secretagogues are WADA-banned
- Hypersensitivity to GHRH analogs or to ipamorelin
Will it work for me?
Establish a baseline (2–3 readings over 1–2 weeks before starting), then track at consistent intervals.
- Tier 1 — Human RCTIGF-1↑· by 8 weeks; target 30–80% rise from baseline, within age-adjusted range — do not chase supraphysiologicPrimary objective marker. IGFBP-3 as confirmatory.
- Tier 3 — Animal / in vitroSleep quality (PSQI), lean mass %, waist circumference↑· 12 weeksFunctional/composition tracking; lags the IGF-1 change.
Your stack
Track this peptide in your protocol — dose, schedule, vials on hand, refill projection. Stays in your browser; no account needed.
Add to my stack